Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 16/20 | 1.00 |
| ▸ | IRAK1 | P51617 | 3/20 | 1.00 |
| ▸ | MTOR | P42345 | 1/20 | 1.00 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.72 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.72 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.72 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.72 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.72 |
| ▸ | CDK1 | P06493 | 1/20 | 0.72 |
| ▸ | PHKG2 | P15735 | 1/20 | 0.72 |
| ▸ | MARK3 | P27448 | 1/20 | 0.72 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.72 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.72 |
| ▸ | CLK2 | P49760 | 1/20 | 0.72 |
| ▸ | GSK3B | P49841 | 1/20 | 0.72 |
| ▸ | NEK4 | P51957 | 1/20 | 0.72 |
| ▸ | CSNK1G2 | P78368 | 1/20 | 0.72 |
| ▸ | ITK | Q08881 | 1/20 | 0.72 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.72 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29363239 | 1.00 | IRAK4 (1.00) | IRAK4IRAK1MTORDYRK3ROCK2 | |
| SCHEMBL175464 | 0.91 | IRAK4 (0.82) | IRAK4IRAK1MTORDYRK3ROCK2 | |
| SCHEMBL3604209 | 0.89 | IRAK4 (0.79) | IRAK4IRAK1MTORDYRK3ROCK2 | |
| SCHEMBL25956628 | 0.86 | IRAK4 (1.00) | IRAK4IRAK1MTORDYRK3ROCK2 | |
| SCHEMBL16261073 | 0.85 | MTOR (0.74) | IRAK4IRAK1MTORKDM4ENPSR1 | |
| SCHEMBL29827291 | 0.85 | IRAK4 (0.89) | IRAK4IRAK1MTORDYRK3ROCK2 | |
| SCHEMBL25956620 | 0.85 | IRAK4 (0.89) | IRAK4IRAK1MTORDYRK3ROCK2 | |
| SCHEMBL18427725 | 0.84 | IRAK4 (1.00) | IRAK4IRAK1MTORDYRK3ROCK2 | |
| SCHEMBL25956637 | 0.84 | IRAK4 (1.00) | IRAK4IRAK1MTORDYRK3ROCK2 | |
| SCHEMBL13500540 | 0.83 | OPRK1 (0.86) | IRAK4IRAK1MTORKDM4ENPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250319091-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | INFINITY PHARMACEUTICALS INC (US) | 2025-10-16 | — | — | US | disclosed |
| US-12213983-B2 | Treatment of cancers using PI3 kinase isoform modulators | INFINITY PHARMACEUTICALS, INC. (US) | 2025-02-04 | — | — | US | disclosed |
| CN-119235863-A | Oral compositions of MK2 pathway inhibitors for the treatment of immune conditions | 阿克拉瑞斯治疗股份有限公司 | 2025-01-03 | — | — | CN | disclosed |
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | ARVINAS OPERATIONS, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | ARVINAS OPERATIONS, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-20240197732-A1 | ORAL COMPOSITIONS OF MK2 PATHWAY INHIBITOR FOR TREATMENT OF IMMUNE CONDITIONS | ACLARIS THERAPEUTICS, INC. | 2024-06-20 | — | — | US | disclosed |
| US-11844801-B2 | Oral compositions of MK2 pathway inhibitor for treatment of immune conditions | ACLARIS THERAPEUTICS, INC. (US) | 2023-12-19 | — | — | US | disclosed |
| US-20230398223-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-12-14 | — | — | US | disclosed |
| US-20230398223-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-12-14 | — | — | US | disclosed |
| US-20230364097-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | INFINITY PHARMACEUTICALS, INC. (US) | 2023-11-16 | — | — | US | disclosed |
| US-7635774-B2 | 2-Amino-imidazole derivatives; modulate the expression and/or function of proteins involved in inflammation, immune response regulation and cell proliferation | AMGEN INC. (US) | 2009-12-22 | — | — | US | disclosed |
| US-7635774-B2 | 2-Amino-imidazole derivatives; modulate the expression and/or function of proteins involved in inflammation, immune response regulation and cell proliferation | AMGEN INC. (US) | 2009-12-22 | — | — | US | disclosed |
| US-7635774-B2 | 2-Amino-imidazole derivatives; modulate the expression and/or function of proteins involved in inflammation, immune response regulation and cell proliferation | AMGEN INC. (US) | 2009-12-22 | — | — | US | disclosed |
| US-20070037803-A1 | 2-Amino-imidazole derivatives; modulate the expression and/or function of proteins involved in inflammation, immune response regulation and cell proliferation | AMGEN SF, LLC (US) | 2007-02-15 | — | — | US | disclosed |
| US-20070037803-A1 | 2-Amino-imidazole derivatives; modulate the expression and/or function of proteins involved in inflammation, immune response regulation and cell proliferation | AMGEN SF, LLC (US) | 2007-02-15 | — | — | US | disclosed |
| US-20070037803-A1 | 2-Amino-imidazole derivatives; modulate the expression and/or function of proteins involved in inflammation, immune response regulation and cell proliferation | AMGEN SF, LLC (US) | 2007-02-15 | — | — | US | disclosed |
| US-7132438-B2 | Benzimidazole derivatives | AMGEN INC. (US) | 2006-11-07 | — | — | US | disclosed |
| EP-1434579-A1 | IMIDAZOLE DERIVATIVES AS ANTIINFLAMMATORY AGENTS | Tularik Inc. (US) | 2004-07-07 | — | — | EP | disclosed |
| US-20030144286-A1 | Benzimidazole derivatives | TULARIK, INC | 2003-07-31 | — | — | US | disclosed |
| WO-2003030902-A1 | IMIDAZOLE DERIVATES AS ANTI-INFLAMMATORY AGENTS | TULARIK INC. (US) | 2003-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12213983-B2 | Treatment of cancers using PI3 kinase isoform modulators | PIK3CA, MCL1, PIK3CB | IRAK4 658/4885IRAK1 754/4885MTOR 280/4885 |
| US-20070037803-A1 | 2-Amino-imidazole derivatives; modulate the expression and/or function of proteins involved in inflammation, immune response regulation and cell proliferation | IDO2, IRF2BP2, IRF3 | IRAK4 102/4885IRAK1 121/4885MTOR 96/4885 |
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | IRAK1, IRAK4, IRAK2 | IRAK4 2/4885IRAK1 1/4885MTOR 919/4885 |
| US-11844801-B2 | Oral compositions of MK2 pathway inhibitor for treatment of immune conditions | RPS6KB2, MKNK2, DUSP2 | IRAK4 96/4885IRAK1 113/4885MTOR 111/4885 |
| US-20030144286-A1 | Benzimidazole derivatives | NFATC1, STAT1, IRF3 | IRAK4 55/4885IRAK1 87/4885MTOR 160/4885 |
| US-20240197732-A1 | ORAL COMPOSITIONS OF MK2 PATHWAY INHIBITOR FOR TREATMENT OF IMMUNE CONDITIONS | RPS6KB2, MKNK2, DUSP2 | IRAK4 96/4885IRAK1 113/4885MTOR 111/4885 |
| US-20250319091-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | PIK3CA, MCL1, PIK3CB | IRAK4 658/4885IRAK1 754/4885MTOR 280/4885 |
| US-20230398223-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | IRAK4 4/4885IRAK1 3/4885MTOR 1433/4885 |
| US-20230364097-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | PIK3CA, MCL1, PIK3CB | IRAK4 658/4885IRAK1 754/4885MTOR 280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.